Year-end Sale % OFF 
Abstract
Radiopharmaceuticals are chemical and biological substances labeled with a radioisotope; they selectively deliver radioisotopes to an organ or tumor tissue through physiological and metabolic processes. The distribution of radiopharmaceuticals can be traced by emitted gamma rays, and radiopharmaceuticals labeled with beta or alpha particle-emitting radioisotopes can destroy tumor cells. Radiopharmaceuticals are used for diagnostic and therapeutic purposes; therapy with a radiopharmaceutical is called targeted radioisotope (radionuclide) therapy (TRT). TRT was established in the 1940s, and radioiodine therapy with 131I has been applied for several decades. TRT is being developed in nonclinical and clinical trials toward the goal of treating a variety of tumors with several new radionuclides and compounds. The dosimetry for TRT is based on the schema recommended by the Society of Nuclear Medicine & Molecular Imaging's Medical Internal Radiation Dose (MIRD) Committee. The pharmacokinetics of radiopharmaceuticals and the energy deposition to the target organ or tissue can be analyzed by using the MIRD. The standard/traditional patient dosimetry for TRT is summarized herein.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
